In vitro activity of daptomycin against multidrug-resistant Staphylococcus aureus and S. aureus with known virulence factors, including community-acquired methicillin-resistant isolates

Diagnostic Microbiology and Infectious Disease

Volumn 61, Issue 3, 2008, Pages 339-342

  Anastasiou, Diane M ^a   Morgan, Margie ^b   Ruane, Peter J ^c   Steenbergen, Judith N ^a   Katz, Bradley D ^a   Alder, Jeff D ^a   Thorne, Grace M ^a  

^a CUBIST PHARMACEUTICALS INC   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c Tower Infectious Diseases ^*  (United States)

Author keywords

Community acquired methicillin resistant Staphylococcus aureus; Daptomycin; Multidrug resistant

Indexed keywords

CIPROFLOXACIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DOXYCYCLINE; ERYTHROMYCIN; GENTAMICIN; HEMOLYSIN; LEVOFLOXACIN; LINEZOLID; OXACILLIN; PANTON VALENTINE LEUKOCIDIN; RIFAMPICIN; STAPHYLOCOCCUS ENTEROTOXIN; TOXIC SHOCK SYNDROME TOXIN 1; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; BACTERIAL STRAIN; DRUG SENSITIVITY; ENDOCARDITIS; GENE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; VIRULENCE;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; DAPTOMYCIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VIRULENCE FACTORS;

EID: 45649083807     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2008.01.012     Document Type: Article

References (18)

1. Akins R.L., and Haase K.K. Gram-positive resistance: pathogens, implications, and treatment options. Pharmacotherapy 25 (2005) 1001-1010
2. Centers for Disease Control and Prevention. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus-Minnesota and North Dakota, 1997-1999. JAMA 12 (1999) 1123-1125
3. Centers for Disease Control and Prevention. Methicillin-resistant Staphylococcus aureus skin infections among competitive sports participants-Colorado, Indiana, Pennsylvania, and Los Angeles County, 2000-2003. Morb. Mort. Wkly. Rep. 52 (2003) 793-795
4. Centers for Disease Control and Prevention. Methicillin-resistant Staphylococcus aureus skin infections in correctional facilities-Georgia, California, and Texas, 2001-2003. Morb. Mort. Wkly. Rep. 52 (2003) 992-996
5. Centers for Disease Control and Prevention. Public health dispatch: outbreaks of community-associated methicillin-resistant Staphylococcus aureus skin infections-Los Angeles, County, California, 2002-2003. Morb. Mort. Wkly. Rep. 52 (2003) 88
6. Centers for Disease Control and Prevention. Update: influenza activity-United States, 2003-2004 season. Morb. Mort. Wkly. Rep. 52 (2003) 1197-1200
7. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. Document M7-A7 (2007), Clinical and Laboratory Standards Institute, Wayne, PA
8. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: Sixteenth Informational Supplement. Document M100-S17 (2007), Clinical and Laboratory Standards Institute, Wayne, PA
9. Fluit A.C., Schmitz F.J., Verhoef J., and Milatovic D. In vitro activity of daptomycin against gram-positive European clinical isolates with defined resistance determinants. Antimicrob. Agents Chemother. 3 (2004) 1007-1011
10. Gonzalez B.E., Reuda A.M., Shelburne S.A.3r., Mushner D.M., Hamil R.J., and Hulten K.G. Community-associated strains of methicillin-resistant Staphylococcus aureus as the cause of healthcare-associated infection. Infect. Control. Hosp. Epidemiol. 10 (2006) 1051-1056
11. Jarraud S., Mougel C., Thioulouse J., Lina G., Meugnier H., Forey F., Nesme X., Etienne J., and Vandenesch F. Relationships between Staphylococcus aureus genetic background, virulence factors, agr groups (alleles), and human disease. Infect. Immun. 70 (2002) 631-641
12. National Nosocomial Infections Surveillance (NNIS) system report. Data summary from January 1992 through June 2004, issued October 2004. Am. J. Infect. Control 8 (2004) 470-485
13. Piper K.E., Steckelberg J.M., and Patel R. In vitro activity of daptomycin against clinical isolates of gram-positive bacteria. J. Infect. Chemother. 4 (2005) 207-209
14. Saravolatz L.D., Pawlak J., and Johnson L.B. Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 2 (2007) 406-409
15. Streit J.M., Jones R.N., and Sader H.S. Daptomycin activity and spectrum: a worldwide sample of 6737 clinical gram-positive organisms. J. Antimicrob. Chemother. 4 (2004) 669-674
16. Thorne G., and Alder J. Daptomycin: a novel lipopeptide antibiotic. Clin. Microbiol. Newsl. 24 (2002) 33-40
17. Tsuji B.T., Rybak M.J., Cheung C.M., Amjad M., and Kaatz G.W.. Community- and health care-associated methicillin-resistant Staphylococcus aureus: a comparison of molecular epidemiology and antimicrobial activities of various agents. Diagn. Microbiol. Infect. Dis. 58 (2007) 41-47
18. Vandenesch F., Naimi T., Enright M.C., Lina G., Nimmo G.R., Heffernan H., Liassine N., Bes M., Greenland T., Reverdy M.E.., and Etienne J. Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg. Infect. Dis. 9 (2003) 978-984